Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Centessa Pharmaceuticals PLC ADR (CNTA)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/16/2025: CNTA (5-star) is a STRONG-BUY. BUY since 9 days. Profits (11.23%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $31.5
1 Year Target Price $31.5
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 132.43% | Avg. Invested days 41 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/16/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.01B USD | Price to earnings Ratio - | 1Y Target Price 31.5 |
Price to earnings Ratio - | 1Y Target Price 31.5 | ||
Volume (30-day avg) 11 | Beta 1.49 | 52 Weeks Range 9.00 - 19.09 | Updated Date 07/16/2025 |
52 Weeks Range 9.00 - 19.09 | Updated Date 07/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.88 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -205.18% |
Management Effectiveness
Return on Assets (TTM) -28.58% | Return on Equity (TTM) -74.44% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1855143050 | Price to Sales(TTM) 134.33 |
Enterprise Value 1855143050 | Price to Sales(TTM) 134.33 | ||
Enterprise Value to Revenue 123.68 | Enterprise Value to EBITDA 1.12 | Shares Outstanding 133619000 | Shares Floating 85935578 |
Shares Outstanding 133619000 | Shares Floating 85935578 | ||
Percent Insiders 0.5 | Percent Institutions 94.42 |
Upturn AI SWOT
Centessa Pharmaceuticals PLC ADR
Company Overview
History and Background
Centessa Pharmaceuticals PLC ADR (CNTX) was formed in 2021 through the combination of 10 private drug discovery and development companies. The company focuses on discovering and developing innovative therapies for patients with high unmet medical needs.
Core Business Areas
- Oncology: Development of therapies for various cancer types.
- Hematology: Development of treatments for blood disorders.
- Immunology: Development of therapies to modulate the immune system.
- Neuroscience: Development of treatments for neurological disorders.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical industry. The organizational structure is based on functional areas, including research and development, clinical development, and commercial operations. CEO is Saurabh Saha.
Top Products and Market Share
Key Offerings
- CTX-009: CTX-009 is a PD-L1 ADC for the treatment of solid tumors. Phase 1/2 trials are ongoing. Competitors include multiple companies developing ADCs such as Seagen (SGEN), ImmunoGen (IMGN).
- CTX-211: CTX-211 is a anti-C4b monoclonal antibody to treat paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases. Phase 1/2 trials are ongoing. Competitors include Alexion/AstraZeneca (AZN) with Soliris and Ultomiris.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and dynamic, with a focus on innovation and addressing unmet medical needs. Trends include the development of targeted therapies, personalized medicine, and digital health solutions.
Positioning
Centessa is a clinical-stage biopharmaceutical company. Its pipeline is focused on novel drug candidates. Competitive advantages include a diversified pipeline, experienced leadership team, and a focus on high-value therapeutic areas.
Total Addressable Market (TAM)
The TAM for the various therapeutic areas Centessa is addressing is in the billions of USD. Centessa's positioning is focused on innovative approaches to underserved patient populations.
Upturn SWOT Analysis
Strengths
- Diversified pipeline
- Experienced leadership team
- Focus on high-value therapeutic areas
- Innovative drug candidates
Weaknesses
- Clinical stage company with no approved products
- Reliance on clinical trial success
- High cash burn rate
- Dependence on financing
Opportunities
- Successful clinical trial outcomes
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition of complementary technologies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- AZN
- SGEN
- IMGN
Competitive Landscape
Centessa competes with large, established pharmaceutical companies and smaller biotech companies. Centessa's advantage lies in its innovative pipeline and focus on addressing unmet medical needs. A disadvantage is its need for clinical trial success for revenue generation.
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth is defined by the expansion of its pipeline and clinical trial progress since its formation in 2021.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates vary widely depending on the perceived likelihood of success of the pipeline programs.
Recent Initiatives: Recent strategic initiatives include initiating and advancing clinical trials for lead programs, forging partnerships, and expanding the scientific team.
Summary
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company with a diversified pipeline. The company is pre-revenue so is dependent on financing and clinical trial successes. Centessa's innovation is promising but very high-risk. Failure of key clinical trials could harm shareholder returns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Centessa Pharmaceuticals PLC ADR investor relations website
- SEC filings
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on your own due diligence and consultation with a qualified financial advisor. Market share estimates are based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Centessa Pharmaceuticals PLC ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-05-28 | CEO & Director Dr. Saurabh Saha M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 86 | Website https://centessa.com |
Full time employees 86 | Website https://centessa.com | ||
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.